Nörokütan Hastalıkların Nefrolojik Bulguları ve Yönetimi
Özet
Nörokutan hastalıklar, merkezi sinir sistemi ve cilt bulgularının yanı sıra sıklıkla böbrek tutulumu gösteren multisistemik bozukluklardır; özellikle Nörofibromatozis tip 1, Tüberoskleroz kompleksi ve Von Hippel-Lindau hastalığı gibi tablolar önemli nefrolojik riskler taşır. Bu hastalıkların yönetimi, hipertansiyon ve vasküler lezyonların erken tespiti ile çok disiplinli bir takip yaklaşımı gerektirir. Tedavi süreçlerinde cerrahi yerine genellikle organ koruyucu girişimler ve farmakolojik yaklaşımlar ön plana çıkmaktadır.
Neurocutaneous diseases are multisystemic disorders that frequently present with renal involvement alongside central nervous system and skin manifestations; conditions such as Neurofibromatosis type 1, Tuberous sclerosis complex, and Von Hippel-Lindau disease pose significant nephrological risks. Management of these conditions requires a multidisciplinary approach focused on the early detection of hypertension and vascular lesions. Treatment processes generally prioritize organ-sparing interventions and pharmacological approaches over surgery.
Referanslar
Mustafa Sahin, Nicole Ullrich, Siddharth Srivastava, and Anna Pinto Neurocutaneous Syndromes. Robert M. Kliegman, Bonita M.D. Stanton, Joseph St. Geme, Nina F Schor (Eds.), Nelson Textbook of Pediatrics. 21nd ed. Philadelphia: Elsevier; 2020. p. 3140-49.
Rosser T. Neurocutaneous Disorders. Continuum (Minneap Minn). Child Neurology. 2018;24(1):96-129.
Aoki Y, Niihori T, Inoue S, Matsubara Y. Recent advances in RASopathies. J Hum Genet. 2016;61(1):33-9.
Johnson KJ, Hussain I, Williams K, Santens R, Mueller NL, Gutmann DH. Development of an international internet-based neurofibromatosis Type 1 patient registry. Contemp Clin Trials. 2013;34(2):305-11.
Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111(6):1355-81.
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45(5):575-8.
Wimmer K. Neurofibromatosis type 1 (NF1) and associated tumors. Klin Padiatr. 2014;226(6-7):309-15.
Feng K, Tong A, Liang Z. Renal artery stenosis due to neurofibromatosis type 1: case report and literature review. Eur J Med Res. 2014;19(1):17.
Criado E. Renal artery stenosis and aneurysms associated with neurofibromatosis. J Vasc Surg. 2005;41(3):539-43.
Terry AR, Jordan JT, Schwamm L, Plotkin SR. Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1: Population-Based Approach. Stroke. 2016;47(1):60-5.
Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.
Patel PA, Stojanovic J. Diagnosis and Treatment of Renovascular Disease in Children. Semin Roentgenol. 2019;54(4):367-83.
Patel PA, Cahill AM. Renovascular hypertension in children. CVIR Endovasc. 2021;4(1):10.
Srinivasan A, Krishnamurthy G, Fontalvo-Herazo L, et al. Spectrum of renal findings in pediatric fibromuscular dysplasia and neurofibromatosis type 1. Pediatr Radiol. 2011;41(3):308-16.
Fossali E, Signorini E, Intermite RC, et al. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol. 2000;14(8-9):806-10.
Trautmann A, Roebuck DJ, McLaren CA, Brennan E, Marks SD, Tullus K. Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension. Pediatr Nephrol. 2017;32(3):495-502.
Teigen CL, Mitchell SE, Venbrux AC, Christenson MJ, McLean RH. Segmental renal artery embolization for treatment of pediatric renovascular hypertension. J Vasc Interv Radiol. 1992;3(1):111-7.
Meyers KE, Cahill AM, Sethna C. Interventions for pediatric renovascular hypertension. Curr Hypertens Rep. 2014;16(4):422.
Zhang B, Zou Y, Yang M, Niu G. Endovascular management of renal artery aneurysms induced by neurofibromatosis type 1: A case report. Medicine (Baltimore). 2017;96(47):e8858.
McCafferty BJ, Gunn AJ, Moawad S, Mahmoud K, Aal AKA, Saddekni S. Endovascular Management of Neurofibromatosis Type I-Associated Vasculopathy: A Case Series and Brief Review of the Literature. Vasc Endovascular Surg. 2020;54(2):182-90.
Eliason JL, Coleman DM, Criado E, et al. Remedial operations for failed endovascular therapy of 32 renal artery stenoses in 24 children. Pediatr Nephrol. 2016;31(5):809-17.
Demarchi I, Genoni G, Prodam F, et al. neurofibromatosi 1 ed ipertensione arteriosa in eta pediatrica: caso clinico [Neurofibromatosis type 1 and hypertension in pediatrics: case report]. Minerva Pediatr. 2011;63(4):335-9.
Villegas L, Cahill AM, Meyers K. Pediatric Renovascular Hypertension: Manifestations and Management. Indian Pediatr. 2020;57(5):443-51.
Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657-68.
Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int. 2006;70(10):1777-82.
Ariceta G, Buj MJ, Furlano M, et al. Recommendations for the management of renal involvement in the tuberous sclerosis complex. Nefrologia. 2020;40(2):142-51.
Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13(12):624-8.
Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255-65.
Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008;452(2):119-32.
Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES. Renal lesion growth in children with tuberous sclerosis complex. J Urol. 1998;160(1):141-5.
Eijkemans MJ, van der Wal W, Reijnders LJ, et al. Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands. Am J Kidney Dis. 2015;66(4):638-45.
Mourikis D, Chatziioannou A, Antoniou A, Kehagias D, Gikas D, Vlahos L. Selective arterial embolization in the management of symptomatic renal angiomyolipomas. Eur J Radiol.1999;32(3):153-9.
Warncke JC, Brodie KE, Grantham EC, et al. Pediatric Renal Angiomyolipomas in Tuberous Sclerosis Complex. J Urol. 2017;197(2):500-6.
Lisa M. Guay-Woodford. Other Cystic Kidney Diseases. John Feehally, Jürgen Floege, Marcello Tonelli, Richard J. Johnson (Eds.). Comprehensive Clinical Nephrology. 6nd ed. London, New York, Philadelphia: Elsevier; 2019. p. 545-559.e1.
Casper KA, Donnelly LF, Chen B, Bissler JJ. Tuberous sclerosis complex: renal imaging findings. Radiology. 2002;225(2):451-6.
Bissler JJ, Siroky BJ, Yin H. Glomerulocystic kidney disease. Pediatr Nephrol. 2010;25(10):2049-56; quiz 2056-9.
Consugar MB, Wong WC, Lundquist PA, et al. CRISP Consortium. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 2008;74(11):1468-79.
Malaga-Dieguez L, Spencer R, Pehrson LJ, et al. Early manifestations of renal disease in patients with tuberous sclerosis complex. Int J Nephrol Renovasc Dis. 2017;10:91-5.
Shapiro RA, Skinner DG, Stanley P, Edelbrock HH. Renal tumors associated with tuberous sclerosis: the case for aggressive surgical management. J Urol. 1984;132(6):1170-4.
Chao DH, Zisman A, Pantuck AJ, Freedland SJ, Said JW, Belldegrun AS. Changing concepts in the management of renal oncocytoma. Urology. 2002;59(5):635-42.
Dechet CB, Bostwick DG, Blute ML, Bryant SC, Zincke H. Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol. 1999;162(1):40-2.
Schillinger F, Montagnac R. Chronic renal failure and its treatment in tuberous sclerosis. Nephrol Dial Transplant. 1996;11(3):481–85.
Devarajan P, Goldstein SL. Acute kidney injury. Karrwal K. Kher, H. William Schnaper, Larry A. Greenbaum (Eds.), Clinical Pediatric Nephrology. 3nd ed. New York: Taylor & Francis Group; 2017. p.571-601.
Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientifc review. Eur J Hum Genet. 2011;19(6):617-23
Gläsker S, Vergauwen E, Koch CA, Kutikov A, Vortmeyer AO. Von Hippel-Lindau Disease: Current Challenges and Future Prospects. Onco Targets Ther. 2020;13:5669-90.
Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf).2008;69(2):181-8.
Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55-64
Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol. 2015;132:139-56.
